DK3380495T3 - Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi - Google Patents
Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi Download PDFInfo
- Publication number
- DK3380495T3 DK3380495T3 DK16867488.5T DK16867488T DK3380495T3 DK 3380495 T3 DK3380495 T3 DK 3380495T3 DK 16867488 T DK16867488 T DK 16867488T DK 3380495 T3 DK3380495 T3 DK 3380495T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- receptor
- cancer
- treatment
- conjugates
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000000863 peptide conjugate Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/083—Neurotensin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259178P | 2015-11-24 | 2015-11-24 | |
| PCT/CA2016/051379 WO2017088058A1 (en) | 2015-11-24 | 2016-11-24 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3380495T3 true DK3380495T3 (da) | 2021-08-16 |
Family
ID=58762819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16867488.5T DK3380495T3 (da) | 2015-11-24 | 2016-11-24 | Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11034727B2 (enExample) |
| EP (2) | EP3380495B1 (enExample) |
| JP (2) | JP6810146B2 (enExample) |
| CN (2) | CN108473541B (enExample) |
| AU (2) | AU2016358324B2 (enExample) |
| CA (2) | CA3071494C (enExample) |
| DK (1) | DK3380495T3 (enExample) |
| ES (1) | ES2882634T3 (enExample) |
| PL (1) | PL3380495T3 (enExample) |
| PT (1) | PT3380495T (enExample) |
| SI (1) | SI3380495T1 (enExample) |
| WO (1) | WO2017088058A1 (enExample) |
| ZA (1) | ZA201804117B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6810146B2 (ja) * | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス．ウ．セ． | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
| EP3625245A4 (en) * | 2017-05-24 | 2020-12-16 | Transfert Plus, S.E.C. | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES |
| US11389460B2 (en) | 2017-09-15 | 2022-07-19 | City Of Hope | Methods and compositions for treating endometrial cancer |
| BR112020015202A2 (pt) * | 2018-03-01 | 2020-12-29 | Glycotope Gmbh | Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15 |
| AU2019324747A1 (en) * | 2018-08-24 | 2021-04-01 | Transfert Plus, S.E.C. | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
| WO2020254683A2 (en) * | 2019-06-20 | 2020-12-24 | Aarhus Universitet | Sorcs2 crystal structure and uses thereof |
| AU2020395148A1 (en) * | 2019-12-06 | 2022-06-23 | Theratechnologies Inc. | Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer |
| US20230338555A1 (en) * | 2020-05-18 | 2023-10-26 | Ionis Pharmaceuticals, Inc. | Conjugated oligonucleotides and uses thereof |
| US20240156971A1 (en) * | 2021-02-26 | 2024-05-16 | Transfert Plus, Société En Commandite | Methods and sortilin binding conjugate compounds for targeting cancer stem cells |
| CN116731113A (zh) * | 2022-03-01 | 2023-09-12 | 上海智肽生物科技有限公司 | 针对sort1的多肽化合物及其药物偶联物 |
| CN120641133A (zh) * | 2022-11-14 | 2025-09-12 | 瑟瑞技术公司 | 用于刺激抗肿瘤免疫应答的药物缀合物化合物 |
| WO2025054707A1 (en) * | 2023-09-11 | 2025-03-20 | Theratechnologies Inc. | Peptide conjugates of camptothecin analogs and uses thereof |
| CN117904303B (zh) * | 2024-03-18 | 2024-06-18 | 湖南宏雅基因技术有限公司 | Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用 |
| CN118384289A (zh) * | 2024-04-24 | 2024-07-26 | 青岛科技大学 | 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| FI101678B1 (fi) | 1990-12-31 | 1998-08-14 | Akzo Nv | Happolabiileja kytkentämolekyylejä |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| US8344211B2 (en) | 2008-08-13 | 2013-01-01 | Ceres, Inc. | Plant nucleotide sequences and corresponding polypeptides |
| TW200634019A (en) | 2004-12-21 | 2006-10-01 | Wyeth Corp | Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors |
| EP2037948B1 (en) * | 2006-05-30 | 2016-04-13 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| EP2077278A1 (fr) * | 2007-12-21 | 2009-07-08 | Centre National de la Recherche Scientifique (CNRS) | Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques |
| CN102131826B (zh) * | 2008-04-27 | 2014-07-02 | H.隆德贝克有限公司 | 人类分拣蛋白的晶体结构及其用于鉴定分拣蛋白的配体的用途 |
| US20120039865A1 (en) * | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8147849B2 (en) | 2009-02-20 | 2012-04-03 | Novartis Ag | Protective antigens for group B Streptococcus hypervirulent strains |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| CA2786255A1 (en) | 2009-12-31 | 2011-07-07 | Organomed Corporation | Formulations from natural products, turmeric, and aspirin |
| EP2740726A1 (en) * | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| LT3280441T (lt) * | 2015-04-07 | 2021-11-25 | Alector Llc | Anti-sortilino antikūnai ir jų naudojimo būdai |
| JP6810146B2 (ja) * | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス．ウ．セ． | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
| EP3625245A4 (en) * | 2017-05-24 | 2020-12-16 | Transfert Plus, S.E.C. | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES |
| AU2019324747A1 (en) * | 2018-08-24 | 2021-04-01 | Transfert Plus, S.E.C. | Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
-
2016
- 2016-11-24 JP JP2018527804A patent/JP6810146B2/ja active Active
- 2016-11-24 CA CA3071494A patent/CA3071494C/en active Active
- 2016-11-24 CN CN201680078822.9A patent/CN108473541B/zh active Active
- 2016-11-24 ES ES16867488T patent/ES2882634T3/es active Active
- 2016-11-24 EP EP16867488.5A patent/EP3380495B1/en active Active
- 2016-11-24 EP EP21174271.3A patent/EP3925969B1/en active Active
- 2016-11-24 US US15/778,626 patent/US11034727B2/en active Active
- 2016-11-24 WO PCT/CA2016/051379 patent/WO2017088058A1/en not_active Ceased
- 2016-11-24 CA CA3006313A patent/CA3006313C/en active Active
- 2016-11-24 SI SI201631303T patent/SI3380495T1/sl unknown
- 2016-11-24 PL PL16867488T patent/PL3380495T3/pl unknown
- 2016-11-24 CN CN202310436312.6A patent/CN116478245A/zh active Pending
- 2016-11-24 DK DK16867488.5T patent/DK3380495T3/da active
- 2016-11-24 AU AU2016358324A patent/AU2016358324B2/en active Active
- 2016-11-24 PT PT168674885T patent/PT3380495T/pt unknown
-
2018
- 2018-06-20 ZA ZA2018/04117A patent/ZA201804117B/en unknown
-
2020
- 2020-08-11 JP JP2020135993A patent/JP7095035B2/ja active Active
-
2021
- 2021-02-19 AU AU2021201085A patent/AU2021201085B2/en active Active
- 2021-04-23 US US17/239,544 patent/US11780882B2/en active Active
-
2023
- 2023-08-30 US US18/240,295 patent/US12269902B2/en active Active
-
2025
- 2025-03-11 US US19/076,662 patent/US20250296957A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3380495T3 (da) | Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi | |
| DK3616720T3 (da) | Farmaceutisk sammensætning til cancerbehandling | |
| EP3651772A4 (en) | ANTI-CANCER POLYTHERAPY | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3319993T3 (da) | AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
| DK3474841T3 (da) | Fremgangsmåder til behandling af ar+-brystkræft | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3430038T3 (da) | Sammensætninger og fremgangsmåder til cd20-immunterapi | |
| DK3624837T3 (da) | Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| PL3622953T3 (pl) | Leczenie skojarzone nowotworu | |
| DK3518932T3 (da) | Behandling af prostatacancer | |
| IL268463A (en) | Cancer treatment | |
| DK3400072T3 (da) | Formuleringer til behandling af blærecancer | |
| DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer | |
| EP3593139C0 (en) | CANCER BIOMARKERS | |
| EP3413927A4 (en) | CANCER THERAPY | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3638293T3 (da) | Sammensætninger til behandling af cancer | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| DK3478284T3 (da) | Forbindelser og sammensætninger til behandling af cancer |